金融界消息 截至2025年7月29日收盘，万孚生物（300482）报收于24.12元，下跌1.03%，换手率3.8%， 成交量16.36万手，成交金额3.92亿元。 通过天眼查大数据分析，广州万孚生物技术股份有限公司共对外投资了37家企业，参与招投标项目1537 次，知识产权方面有商标信息397条，专利信息729条，此外企业还拥有行政许可1844个。 来源：金融界 万孚生物最新一期业绩显示，截至2025一季报，公司营业总收入8.00亿元、同比减少7.06%，归属净利 润1.89亿元，同比减少13.37%，扣非净利润1.72亿元，同比减少17.57%，流动比率5.781、速动比率 5.298、资产负债率18.69%。 天眼查商业履历信息显示，广州万孚生物技术股份有限公司，成立于1992年，位于广州市，是一家以从 事研究和试验发展为主的企业。企业注册资本47134.2537万人民币，实缴资本29308.7423万人民币。公 司法定代表人为王继华。 资金流向方面，今日主力资金净流出2100.11万元，占比成交额5.35%。其中，超大单净流出574.66万 元、占成交额1.46%，大单净流出1525.44万元、占成交 ...

Group 1 - Wanfu Bio's subsidiary, Tianshen Medical, has recently received approval from the National Medical Products Administration and Guangdong Provincial Medical Products Administration for 9 self-developed test kits, including thrombosis and tumor marker test kits, enhancing clinical testing options [1] - Tianshen Medical specializes in cardiovascular diagnostics and offers a comprehensive range of cardiac marker testing products, including hs-Tnl, cTnl, Myo, CK-MB, BNP, NT-proBNP, D-Dimer, and H-FABP [1] - The newly approved thrombosis five-item test (TAT, PIC, TM, t-PAIC, FDP) is designed for whole blood samples and provides early indicators of changes in the vascular endothelium, coagulation, and fibrinolysis systems, making it suitable for thrombotic risk assessment and early diagnosis [1] Group 2 - The newly approved thrombosis five-item test combined with D-Dimer will aid in the auxiliary diagnosis of thrombotic diseases, early diagnosis of DIC, monitoring of thrombolytic and anticoagulant drug efficacy, and diagnosis of vascular endothelial system damage, offering clinicians more comprehensive and precise diagnostic tools [2] - As of July 2025, Wanfu Bio's single-use chemiluminescence system has obtained 16 medical device registration certificates for tumor marker testing, making it the most comprehensive small-scale luminescence system in China [2] - Wanfu Bio has launched various fully automated chemiluminescence immunoassay analyzers with different throughput for diverse applications, holding over 150 medical device registration certificates globally, covering 9 major testing areas including cardiac markers, inflammation, thrombosis, thyroid, sex hormones, anemia, bone metabolism, tumors, and infectious diseases [2] - The company plans to continue leveraging its high-level, global R&D innovation system, focusing on technological, product, and service innovations [2]

（编辑 姚尧） 证券日报网讯 7月29日晚间，万孚生物发布公告称，公司全资子公司深圳天深医疗器械有限公司近日收 到国家药品监督管理局及广东省药品监督管理局颁发的医疗器械注册证，包括组织型纤溶酶原激活剂- 抑制剂1复合物测定试剂盒（化学发光免疫分析法）等。 ...

Core Viewpoint - Wanfu Biology's subsidiary, Tianshen Medical, has received approval for nine self-developed test kits from the National Medical Products Administration and Guangdong Provincial Drug Administration, enhancing clinical testing options [1] Group 1: Product Development - The approved test kits include thrombosis five-item tests and tumor marker tests, providing a richer testing menu and more convenient combinations for clinical use [1] - By July 2025, Wanfu Biology's single-use chemiluminescence system is expected to have obtained 16 medical device registration certificates for tumor marker detection, making it the most comprehensive small-scale luminescence system in China [1] Group 2: Market Position - Wanfu Biology's single-use chemiluminescence product line has received over 150 medical device registration certificates globally, covering nine major testing areas including cardiac markers, inflammation, thrombosis, thyroid, sex hormones, anemia, bone metabolism, tumors, and infectious diseases [1]

Group 1 - The company Wanfu Bio announced that its wholly-owned subsidiary Shenzhen Tianshen Medical Device Co., Ltd. has received 9 medical device registration certificates from the National Medical Products Administration and Guangdong Provincial Medical Products Administration [1] - The registered products include thrombosis detection reagents and tumor marker detection reagents [1]

Group 1 - Anhui Construction won a joint bid for the Chongqing Rongchang to Sichuan Zigong expressway project, with a total estimated investment of 3.614 billion yuan and a construction period of 3 years [1] - Hongfa Co. reported a net profit of 964 million yuan for the first half of 2025, a year-on-year increase of 14.19%, with revenue of 8.347 billion yuan, up 15.43% [1][2] - Lujiazui's net profit for the first half of 2025 was 815 million yuan, a decrease of 7.87%, despite a revenue increase of 33.91% to 6.598 billion yuan [3] - Enhua Pharmaceutical achieved a net profit of 700 million yuan, up 11.38%, with revenue of 3.010 billion yuan, an increase of 8.93% [4][5] - China CNR signed several major contracts totaling approximately 32.92 billion yuan, covering various sectors including urban rail vehicles and wind power equipment [6] - WanTong Intelligent signed an exclusive sales and cooperation agreement in the embodied intelligence field, gaining global sales rights for specific chip-based products [7][8] Group 2 - Liansheng Technology's subsidiary received a government subsidy of 13.5 million yuan, accounting for 12.24% of the company's latest audited net profit [9] - Guobang Pharmaceutical reported a net profit of 456 million yuan, a year-on-year increase of 12.60%, with revenue of 3.026 billion yuan, up 4.63% [10] - Baotai expects a net loss of 110 to 140 million yuan for the first half of 2025, a reduction in loss compared to the previous year [11] - Sains expects a net profit decrease of 57.53% to 60.13%, with projected revenue growth of 15.17% to 23.59% [12] - Nanya New Materials anticipates a net profit of 80 to 95 million yuan for the first half of 2025, an increase compared to the previous year [13] - Tian Pharmaceutical's subsidiary passed the consistency evaluation for a peritoneal dialysis solution [14] Group 3 - Shede Liquor announced the resignation of director Ni Qiang due to work reasons [15] - Greentown Water plans to transfer assets and liabilities of its ASEAN subsidiary to improve resource allocation [16] - Beibu Gulf Port's subsidiary signed an associated transaction contract worth 11.199 million yuan [17] - Beibu Gulf Port announced multiple resignations of directors and executives [18] - Jidian Co. reported the resignation of its deputy general manager due to work changes [19] - Wanhua Chemical's industrial park in Fujian resumed production after maintenance [20] Group 4 - Shanghai Pharmaceuticals received approval for a clinical trial of a new indication for its B019 injection [21] - Jianbang Co. reported a net profit of 69.66 million yuan, a decrease of 27.72%, with revenue of 307 million yuan, down 15.37% [23] - Jianbang Co. plans to use up to 400 million yuan of idle funds for cash management [25] - Wanfu Bio's subsidiary obtained multiple medical device registrations [28] - Hunan Tianyan announced a change in its controlling shareholder to China Chang'an Automobile Group [29][30] - Xizhuang Co. plans to establish a joint venture for sustainable aviation fuel [32]

Core Viewpoint - Wanfu Biological's stock closed at 24.12 yuan, down 1.03%, with a rolling PE ratio of 21.81 times and a total market value of 11.612 billion yuan, indicating a lower valuation compared to the industry average [1][2] Company Overview - Guangzhou Wanfu Biological Technology Co., Ltd. specializes in the research, production, and marketing of rapid diagnostic reagents and related instruments, focusing on infectious disease testing, chronic disease testing, pregnancy and reproductive health testing, and drug abuse testing [1] - The company has received numerous accolades, including being recognized as a key high-tech enterprise under the National Torch Program and a national-level "green factory" in January 2025 [1] Financial Performance - For Q1 2025, the company reported an operating income of 800 million yuan, a year-on-year decrease of 7.06%, and a net profit of 189 million yuan, down 13.37% year-on-year, with a gross profit margin of 66.67% [2] - The company's PE ratio (TTM) stands at 21.81, while the industry average is 55.46, indicating a significant valuation gap [2] Industry Comparison - In the medical device industry, Wanfu Biological ranks 46th in terms of PE ratio, with the industry median at 37.74 times [1][2] - Other companies in the industry have varying PE ratios, with the highest being 20.02 for Sanxin Medical and the lowest at 10.94 for Jiuan Medical [2]

每经AI快讯，万孚生物(300482)7月29日晚间公告，公司全资子公司深圳天深医疗器械有限公司近日收 到国家药品监督管理局及广东省药品监督管理局颁发的医疗器械注册证，包括血栓五项检测试剂和肿瘤 标志物检测试剂等。 （文章来源：每日经济新闻） ...

Group 1 - The fentanyl concept index declined by 0.88%, ranking among the top declines in the concept sector as of July 29 [1] - Within the fentanyl sector, companies such as Botao Bio, Enhua Pharmaceutical, and Wanfu Bio experienced significant declines, while three companies, including China National Pharmaceutical Modern, Lingrui Pharmaceutical, and Renfu Pharmaceutical, saw slight increases of 1.07%, 0.17%, and 0.09% respectively [1] Group 2 - The fentanyl concept sector experienced a net outflow of 80 million yuan in capital today, with six stocks seeing net outflows, and five stocks with outflows exceeding 10 million yuan [2] - Renfu Pharmaceutical had the highest net outflow of 18.1651 million yuan, followed by Dongfang Bio, Enhua Pharmaceutical, and Wanfu Bio with net outflows of 16.8542 million yuan, 16.6752 million yuan, and 15.9620 million yuan respectively [2] - The top net inflow stocks in the fentanyl concept sector included China National Pharmaceutical Modern and China National Pharmaceutical, with net inflows of 9.5225 million yuan and 1.2608 million yuan respectively [2]

| 证券代码：300482 | 证券简称：万孚生物 | 公告编号：2025-037 | | --- | --- | --- | | 债券代码：123064 | 债券简称：万孚转债 | | 广州万孚生物技术股份有限公司 天深医疗单人份化学发光产品线已推出多款不同通量的全自动化学发光免 疫分析仪，全球范围内获得医疗器械产品注册证 150 余项，检测菜单涵盖心标、 炎症、血栓、甲状腺、性激素、贫血、骨代谢及肿瘤、传染病检测等 9 大领域。 未来，万孚生物将持续依托高水平、全球化的研发创新体系，坚持技术创新、产 品创新和服务创新，让生物科技惠及万众。 公司未来会积极推动相关产品的销售，为广大股东创造更大的价值。上述产 品目前尚无法预测产品对公司业绩的影响，敬请投资者注意投资风险。 广州万孚生物技术股份有限公司（以下简称"万孚生物"或"公司"）全资 子公司深圳天深医疗器械有限公司（以下简称"天深医疗"）近日收到国家药品 监督管理局及广东省药品监督管理局颁发的医疗器械注册证，具体信息如下： | 名称 | 注册证号 | 有效期至 | 预期用途 | | --- | --- | --- | --- | | 组织型纤溶酶原激活 ...